Physician profile
Judith Moss
NPI 1013942317
$1,952.84
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $321 · 2021: $155 · 2022: $457 · 2023: $134 · 2024: $60.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $350.83 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $277.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.23 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $145.36 | 2019-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $126.92 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $85.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $78.40 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.21 | 2019-2020 | |
| Amarin Pharma, INC. | $70.44 | 2019-2022 | |
| Amgen INC. | $64.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.77 | 2019-2022 | |
| Allergan, INC. | $56.13 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.46 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.63 | 2020 | |
| Phadia US INC. | $22.28 | 2022 | |
| Horizon Therapeutics Plc | $20.06 | 2019 | |
| Ibsa Pharma INC. | $18.47 | 2019 | |
| Esperion Therapeutics, INC. | $16.00 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.69 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.53 | 2022 | |
| Neos Therapeutics, LP | $13.25 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.37 | 2019 | |
| Neuronetics, INC. | $9.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.